Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses

Abstract

T cell responses in vivo. p53-null tumors also show an accumulation of suppressive regulatory T (Treg) cells. Finally, we show that two key drivers of tumorigenesis, activation of KRAS and deletion of p53, cooperate to promote immune tolerance.